China Pituitary Disease Registry (CAPASITY)

Study Overview
=================
Brief Summary
-----------------
Epidemiologic studies have revealed a tremendous increase in the prevalence of pituitary disease and related mortality worldwide. In order to meet all the challenges in the treatment of pituitary disease in China, CAPASITY was founded in 2020. The objective of CAPASITY is to launch a pituitary disease management model based on the Internet health information platform. It allows the application and evaluation of pituitary disease treatment strategies at multiple centers. The proprietary electronic medical database will help the dynamic big-data analysis in epidemiology of pituitary disease, diagnosis, and treatment.

Detailed Description
-----------------
In order to meet all the challenges in the diagnosis and treatment of pituitary diseases in China, CAPASITY was founded in 2020. With advanced medical equipment and Internet of Things (IoT) technology, CAPASITY is committed to creating an online and offline integrated solution for pituitary disease, and for the entire spectrum of pituitary disease, to achieve a more convenient and precise model of care for patients. aiming to establish a platform with diagnosis and treatment of pituitary disease and their long-term follow-up. It allows the application and evaluation of treatment strategies at these centers. Objective: The purpose of the present study is to establish a multi-center nationwide prospective database of patients with pituitary adenomas to explore the epidemiology, biochemical, and clinical outcome related to pituitary tumors and its complications, as well as other pituitary disease. To collect cross-sectional data from patients seen and treated at each center so as to evaluate: the current status of care of patients with pituitary disease and its related complications, as well as other risk factors treatment strategies at multiple centers. To collect the prospective data of patients treated at each center in order to evaluate the strategies for the achievement of treatment goals, changes in management, control of risk factors, incidence and progression of related clinical endpoints (including mortality), behavioral changes, as well as QoL. Methods: After obtaining informed consent, patients will be invited and initiated with a comprehensive baseline evaluation at each CAPASITY center. Then patients will be followed by clinical/laboratory visits on according to individualized patient's treatment plans. A repeated comprehensive clinical and laboratory assessment for hormones and imaging, as well as complications will be scheduled once a year.

Official Title
-----------------
China Pituitary Disease Registry Study

Conditions
-----------------
Pituitary Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years old and ≤ 75 years Patients diagnosed with pituitary adenomas, and other pituitary diseases Pituitary adenomas resected by transsphenoidal surgery were identified by histological diagnoses. Gender: males and females Provide written informed consent Satisfactory compliance Exclusion Criteria: Patients with significantly reduced life expectancy (less than 2 years) With Drug abuse With AIDS or syphilis or infectious diseases such as viral tuberculosis in active phase at enrollment

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percentage of functional pituitary adenoma | percentage of PRLoma, GHoma, ACTHoma, and etc | through study completion, an average of 1 year | 
| remission and recurrence rate of pituitary surgery | treatment outcome of pituitary adenoma. Results will be dichotomized as remission, persistence or recurrence. | through study completion, an average of 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| concentration of GH | changes in GH | through study completion, an average of 1 year | 
| concentration of IGF-1 | changes in IGF-1 | through study completion, an average of 1 year | 
| concentration of PRL | changes in PRL | through study completion, an average of 1 year | 
| concentration of ACTH | changes in ACTH | through study completion, an average of 1 year | 
| concentration of cortisol | changes in cortisol | through study completion, an average of 1 year | 
| concentration of fT3 | changes in fT3 | through study completion, an average of 1 year | 
| concentration of fT4 | changes in fT4 | through study completion, an average of 1 year | 
| concentration of TSH | changes in TSH | through study completion, an average of 1 year | 
| pituitary MRI | changes in MRI of sellar area | through study completion, an average of 1 year | 
| percentage of hypopituitarism | percentage of hypopituitarism | through study completion, an average of 1 year | 
| percentage of diabetes insipidus, etc | percentage of diabetes insipidus, etc | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pituitary Disease, Pituitary Adenoma